Name: Abiraterone
Brand: Selleck Chemicals
SKU: S1123
Availability: InStock
Rating: 5 (32 reviews)

Jump to

Quality Control

Batch: Purity: 99.99%

99.99

Related Targets	Dehydrogenase HSP Transferase PDE phosphatase PPAR Vitamin Carbohydrate Metabolism Mitochondrial Metabolism Drug Metabolite
Other P450 (e.g. CYP17) Inhibitors	Apigenin Baicalein Avasimibe Naringenin Diosmetin Sodium Danshensu Alizarin Naringin Benzbromarone Orteronel

Cell Culture, Treatment & Working Concentration

Cell Lines	Assay Type	Incubation Time	Activity Description	PMID
JM109	Growth inhibition assay		Inhibition of C-terminal His-tagged recombinant human CYP17A1delta19H mutant expressed in Escherichia coli JM109 cells assessed as decrease in progesterone hydroxylation in presence of cytochrome P450 reductase by HPLC-UV method, IC50=0.0094μM.	29792703
P450c17-LNCaP	Growth inhibition assay		In vitro cytochrome P450 17A1 inhibition was assayed using the rapid acetic acid releasing assay (AARA), utilizing intact P450c17-expressing Escherichia coli or P450c17-LNCaP cells as the enzyme source, IC50=0.8μM.	12773039
V79MZh11B1	Growth inhibition assay		Inhibition of human CYP11B1 expressed in hamster V79MZh11B1 cells, IC50=1.608μM.	18672868
V79MZh11B1	Growth inhibition assay		Inhibition of recombinant CYP11B1 expressed in expressed in V79MZh11B1 cells, IC50=1.608μM.	19211174
V79MZh	Growth inhibition assay		Inhibition of human CYP11B1 expressed in hamster V79MZh cells, IC50=1.61μM.	20550118
V79MZh	Growth inhibition assay		Inhibition of human CYP11B1 expressed in hamster V79MZh cells using [1,2-3H]-11-deoxycorticosterone as substrate, IC50=1.61μM.	23859149
V79MZh	Growth inhibition assay		Inhibition of human CYP11B2 expressed in hamster V79MZh cells, IC50=1.75μM.	20550118
V79MZh	Growth inhibition assay		Inhibition of human CYP11B2 expressed in hamster V79MZh cells using [1,2-3H]-11-deoxycorticosterone as substrate, IC50=1.75μM.	23859149
V79MZh11B2	Growth inhibition assay		Inhibition of human CYP11B2 expressed in hamster V79MZh11B2 cells, IC50=1.751μM.	18672868
LNCAP	Antiproliferative assay	72 hrs	Antiproliferative activity against human LNCAP cells after 72 hrs by MTT assay, IC50=3.29μM.	29310026
hTERT-BJ	Cytotoxicity assay	48 hrs	Cytotoxicity against human hTERT-BJ cells assessed as cell growth inhibition after 48 hrs SRB assay, GI50=4.5μM.	29172080
PC3	Antiproliferative assay	72 hrs	Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay, IC50=5.94μM.	29310026
MGC803	Antiproliferative assay	72 hrs	Antiproliferative activity against human MGC803 cells after 72 hrs by MTT assay, IC50=7.72μM.	29310026
HeLa	Antiproliferative assay	48 hrs	Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay, GI50=7.9μM.	29172080
PC3	Cytotoxicity assay	48 hrs	Cytotoxicity against human PC3 cells assessed as growth inhibition after 48 hrs by MTT assay, IC50=9.32μM.	24148837
GES-1	Antiproliferative assay	72 hrs	Antiproliferative activity against human GES-1 cells after 72 hrs by MTT assay, IC50=13.12μM.	29310026
T47D	Growth inhibition assay	72 hrs	Growth inhibition of human T47D cells after 72 hrs by MTT assay, IC50=16.9μM.	27209562
MDA-MB-231	Growth inhibition assay	72 hrs	Growth inhibition of human MDA-MB-231 cells after 72 hrs by MTT assay, IC50=19.2μM.	27209562
MCF7	Growth inhibition assay	72 hrs	Growth inhibition of human MCF7 cells after 72 hrs by MTT assay, IC50=19.3μM.	27209562
MDA-MB-361	Growth inhibition assay	72 hrs	Growth inhibition of human MDA-MB-361 cells after 72 hrs by MTT assay, IC50=20.4μM.	27209562
T47D	Antiproliferative assay	48 hrs	Antiproliferative activity against human T47D cells after 48 hrs by SRB assay, GI50=24μM.	29172080
WiDr	Antiproliferative assay	48 hrs	Antiproliferative activity against human WiDr cells after 48 hrs by SRB assay, GI50=42μM.	29172080
Click to View More Cell Line Experimental Data

Solubility

In vitro
Batch:

Ethanol : 0.2 mg/mL

DMSO : 0.1 mg/mL (0.28 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : 0.02 mg/mL

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.075mg/ml (0.21mM)	Taking the 1 mL working solution as an example, add 50 μL of 1.5 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.075mg/ml (0.21mM)	Taking the 1 mL working solution as an example, add 50 μL of 1.5 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	349.51	Formula	C₂₄H₃₁NO	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	154229-19-3	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	CB-7598			Smiles	CC12CCC(CC1=CCC3C2CCC4(C3CC=C4C5=CN=CC=C5)C)O

Mechanism of Action

Features	Approved for the treatment of docetaxel-treated castration-resistant prostate cancer.
Targets/IC₅₀/Ki	CYP17 (Cell-free assay) 2 nM
In vitro	Abiraterone binds and inhibits wild-type and mutant androgen receptor (AR). This compound inhibits in vitro proliferation and androgen receptor-regulated gene expression of androgen receptor-positive prostate cancer cells, which could be explained by androgen receptor antagonism in addition to inhibition of steroidogenesis. In fact, activation of mutant androgen receptor by eplerenone is inhibited by greater concentrations of this chemical. It displaces ligand from both WT-AR and T877A with EC50 of 13.4 μM and 7.9 μM, respectively. This compound inhibits lyase activity with an IC50 of 5.8 nM in rat testis microsomes. Abiraterone acetate significantly inhibits T secretion (−48%) and in turn increased LH concentration (192%).
Kinase Assay	C_17,20-lyase activity assay
Kinase Assay	Microsomes are diluted to a final protein concentration of 50 μg/mL in the reaction mixture which contained 0.25 M sucrose, 20 mM Tris–HCl (pH 7.4), 10 mM G6P and 1.2 IU/mL G6PDH. After equilibration at 37 °C for 10 minutes, the reaction is initiated by addition of βNADP to obtain a final concentration of 0.6 mM. Prior to the distribution of 600 μL of the reaction mixture in each tube, Abiraterone is evaporated to dryness under a stream of nitrogen and then are incubated at 37 °C for 10 minutes. After incubation with this compound, 500 μL of the reaction mixture is transferred to tubes containing 1 μM of the enzyme substrate, 17OHP. After a further 10 minutes incubation, tubes are placed on ice and the reaction is stopped by addition of 0.1 ml NaOH 1N. Tubes are deep-frozen and stored at −20 °C until assayed for Δ4A levels. A Δ4A RIA is developed and automated on a microplate format using a specific antibody against Δ4A. The separation of free and bound antigen is achieved with a dextran-coated charcoal suspension. After centrifugation, aliquots of the clear supernatant are counted in duplicates in a 1450 MicrobetaPlus liquid scintillation counter. The Δ4A concentrations of unknown samples are determined from the standard curve. The detection limit is 0.5 ng/mL and the within and between assay coefficients of variation are 10.7 and 17.6%, respectively at an assay value of 13 ng/mL. The rate of enzymatic reaction is expressed as pmol of Δ4A formed per 10 minutes and per mg of protein. The value of maximum activity without inhibitor (control) is set at 100%. The IC50 values are calculated using non-linear analysis from the plot of enzyme activity (%) against log of inhibitor concentration.
In vivo	Abiraterone inhibits CYP17 with an IC50 of 72 nM, in human testicular microsomes. This compound fails to significantly reduce the size of any of the organs. It reduces the testosterone levels strongly, almost reaching the level of the orchiectomy control. The testosterone levels are reduced by this chemical for more than 95% compared to the control group.
References	[1] https://pubmed.ncbi.nlm.nih.gov/18645193/ [2] https://pubmed.ncbi.nlm.nih.gov/22411952/ [3] https://pubmed.ncbi.nlm.nih.gov/12767278/ [4] https://pubmed.ncbi.nlm.nih.gov/20684610/ [5] https://pubmed.ncbi.nlm.nih.gov/21729712/ [6] https://pubmed.ncbi.nlm.nih.gov/12767280/

Applications

Methods	Biomarkers	Images	PMID
Western blot	eIF4E / eIF4G / eIF4E / eIF4G / AR p-4EBP1 / 4EBP1		22174412

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06014853	Completed	Prostate Cancer	Bukwang Pharmaceutical\|Dyna Therapeutics	August 10 2023	Phase 1
NCT03348670	Active not recruiting	Prostate Cancer	Han Xu M.D. Ph.D. FAPCR Sponsor-Investigator IRB Chair\|Medicine Invention Design Inc	August 18 2023	Phase 2\|Phase 3
NCT05737082	Completed	Healthy	Hanmi Pharmaceutical Company Limited	March 30 2023	Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Abiraterone P450 (e.g. CYP17) inhibitor

Chemical Structure

Molecular Weight: 349.51